Gain Therapeutics SA maakt bekend dat Jeffrey Riley toetreedt tot raad van bestuur
LUGANO, Zwitserland (BUSINESS WIRE) – Gain Therapeutics SA, een biotechnologiebedrijf dat nieuwe therapieën ontdekt en ontwikkelt voor de bestrijding van lysosomale enzymen die betrokken zijn bij aangeboren stofwisselingsfouten en ziekten van het CZS, heeft aangekondigd dat Jeffrey Riley als onafhankelijk lid van de raad van bestuur is toegetreden tot Gain Therapeutics.
De heer Riley heeft meer dan 25 jaar ervaring in de biotechnologische en farmaceutische industrie, waarbij hij wereldwijd tal van strategische bedrijfsallianties heeft onderhandeld, joint ventures heeft opgericht en heeft geassisteerd in durfkapitaalinvesteringen ter ondersteuning van productontwikkeling. Hij heeft meer dan $1,5B aan eigen en vreemd vermogen opgehaald. Hij heeft gewerkt voor grote farmaceutische bedrijven (SmithKline Beecham en Pfizer), risicokapitaal (Queensland Biocapital Fund / QIC) en talrijke biotechnologiebedrijven in de hoedanigheid van business development en algemeen management.
Gain Therapeutics SA Announces Jeffrey Riley to join its Board of Directors
LUGANO, Switzerland–(BUSINESS WIRE)– Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in CNS diseases, today announced that Mr. Jeffrey Riley joined Gain Therapeutics as Independent Board Member.
Mr. Riley has more than 25 years of experience in the biotechnology and pharmaceutical industries, during which he has negotiated numerous worldwide strategic corporate alliances, established joint ventures and assisted in venture financings to support product development. He has raised over $1.5B in equity and debt instruments. He has worked for big pharma (SmithKline Beecham and Pfizer), venture capital (Queensland Biocapital Fund / QIC) and numerous biotechnology companies in his capacity of business development and general management.
“We are delighted to have Jeff join us as an independent board member,” said Dr. Khalid Islam, Chairman of the Board of Gain Therapeutics SA. “Jeff’s perspective, based on his distinguished career and leadership roles in R&D organizations and his transactional expertise will be very valuable to the board as the company seeks to execute on its global product discovery and development strategy.”
“I am delighted to join Gain Therapeutics and support its endeavors to bring to patients brain penetrant small molecule able to regulate misfolded enzymes involved in rare pediatric diseases and in neurodegenerative disease for which high unmet medical needs still exist.” Said Mr. Jeffrey Riley, Independent Board member of Gain Therapeutics.
About Gain Therapeutics SA
Gain Therapeutics SA is a Swiss biotech company specializing in the discovery of new drugs for rare and CNS diseases. The company targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs. Gain Therapeutics SA is developing a new class of compounds: structurally targeted allosteric regulators, identified through its pioneering proprietary platform – SEE-Tx.
https://www.gaintherapeutics.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190911005392/en/
Contacts
For Gain Therapeutics SA
Dr. Manolo Bellotto, General Manager
+41 91 921 1524
mbellotto@gaintherapeutics.com
Check out our twitter: @NewsNovumpr